Menu
Live News EQUITY M impact

CRDO: Credo Initiated

Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis

AGMBCNXUCRDOFTHSPCX

Top Wall Street analysts changed their outlook on these top names.

For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page .

HC Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on Conexeu Sciences Inc (NASDAQ: CNXU ) with a Buy rating and announced a price target of $20.

Conexeu Sciences shares closed at $13.28 on Thursday.

See how other analysts view this stock .

Evercore ISI Group analyst Mark Lipacis initiated coverage on Credo Technology Group Holding Ltd (NASDAQ: CRDO ) with an Outperform rating and announced a price target of $325.

Credo Technology shares closed at $271.83 on Thursday.

See how other analysts view this stock .

HC Wainwright & Co. analyst Patrick R.

Trucchio initiated coverage on Agomab Therapeutics NV (NASDAQ: AGMB ) with a Buy rating and announced a price target of $35.

AgomAb Therapeutics shares closed at $10.98 on Thursday.

See how other analysts view this stock .

Keybanc analyst Michael Leshock initiated coverage on Space Exploration Technologies Corp (NASDAQ: SPCX ) with a Sector Weight rating.

SpaceX shares closed at $185.00 on Thursday.

See how other analysts view this stock .

HC Wainwright & Co. analyst Patrick R.

Trucchio initiated coverage on Faeth Therapeutics, Inc . (NASDAQ: FTH ) with a Buy rating and announced a price target of $60.

Faeth Therapeutics shares closed at $17.82 on Thursday.

See how other analysts view this stock.

Considering buying CRDO stock? Here’s what analysts think: Photo via Shutterstock